ALNYLAM PHARMACEUTICALS, INC.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics, treating diseases by silencing disease-causing genes. Its approved and pipeline products target conditions such as hereditary ATTR amyloidosis, primary hyperoxaluria, and acute hepatic porphyria.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| SUPRAN BRYANEVP, CLO and Secretary | Sell | $399K | 1,758at $226.88 | Oct 2, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
| Member | Chamber | Type | Amount | Date |
|---|---|---|---|---|
| Cory A BookerBooker, Cory (Senator) | Senate | Sell | $1,001 - $15,000 | Aug 11, 2026 |
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ALNY activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.